Real-world siponimod use in secondary progressive multiple sclerosis: the RESYZE study.

ABSTRACT:

Background

Siponimod is approved in Europe for active secondary progressive multiple sclerosis (SPMS), but real-world data on its treatment patterns and outcomes in people with SPMS (pwSPMS) is limited.

Objective

To assess the demographic and clinical characteristics, effectiveness, and safety of siponimod in pwSPMS in a real-world setting.

Design

Non-interventional/observational, retrospective, multicenter study (28 centers).

Methods

Patients (⩾18 years) with active SPMS treated with siponimod in routine care were included. Retrospective clinical, radiological, and laboratory data were collected for patients up to 24 months before and 12 months after siponimod treatment.

Results

In total, 210 participants were included (mean age: 52.5 ± 8.6 years; femal

SUBMITTER: Oreja-Guevara C 

PROVIDER: S-EPMC13473779 | biostudies-literature | 2026

REPOSITORIES: biostudies-literature